AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BLACKSTONE MINERALS LTD

0.034

-0.001-2.86%

Volume:320.33K

Turnover:10.90K

Market Cap:58.46M

PE:-3.97

High:0.035

Open:0.034

Low:0.034

Close:0.035

52wk High:0.085

52wk Low:0.028

Shares:1.72B

Float Shares:1.38B

Volume Ratio:0.50

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.009

EPS(LYR):-0.009

ROE:-11.34%

ROA:-5.95%

PB:0.67

PE(LYR):-3.97

Loading ...

Overview Company News Filings

Evercore ISI Adjusts Price Target on Boston Scientific to $52 From $65

MT Newswires Live

Citigroup Adjusts Price Target on Boston Scientific to $48 From $50, Keeps Neutral Rating

MT Newswires Live

Oppenheimer Adjusts Price Target on Boston Scientific to $65 From $85, Maintains Outperform Rating

MT Newswires Live

Boston Scientific Shares Fall After Citigroup Downgrade

MT Newswires Live

Citigroup Downgrades Boston Scientific to Neutral From Buy, Adjusts Price Target to $50 From $57

MT Newswires Live

Boston Scientific Cyberattack Could Extend Rebound Timeline, Truist Says

MT Newswires Live

Resmed Inc Stock (RMD) Moved Down by 3.15% on Sep 8: What Investors Need To Know

Update: Boston Scientific Shares Fall After Catheter Recall

MT Newswires Live

Boston Scientific Recalling Thousands of Percutaneous Catheters

MT Newswires Live

Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday

MT Newswires Live

Should Boston Scientific’s Shift Toward Capital Spending and External Innovation Require Action From (BSX) Investors?

Simply Wall St.

Boston Scientific (BSX) Rebounds Sharply, Is The Stock Still A Bargain?

Simply Wall St.

Resmed Inc Stock (RMD) Moved Up by 3.01% on Aug 10: Key Drivers Unveiled

Why Boston Scientific (BSX) Is Up 5.6% After Mixed Q2, Recall News And Guidance Update

Simply Wall St.

Boston Scientific (BSX) Stock Ignores Margin Strength As Growth Outlook Softens

Simply Wall St.

Boston Scientific's Watchman Slowdown Raises Utilization Questions, Oppenheimer Says

MT Newswires Live

Boston Scientific Lowered Full-Year Guidance on Headwinds in Electrophysiology, Watchman Portfolios, RBC Says

MT Newswires Live

GUIDANCE: (BSX) Boston Scientific Expects 2026 Adjusted EPS Range $3.28 to $3.32, vs. FactSet Est of $3.36

MT Newswires Live

Boston Scientific (BSX) Recalls Rapid Refill Injection System Over Syringe Detachment Risk

Simply Wall St.

Boston Scientific Has Underappreciated Growth Drivers, UBS Says

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/BSX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BSX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BSX.AU\",,,,,undefined,":{"symbol":"BSX.AU","market":"AU","secType":"STK","nameCN":"BLACKSTONE MINERALS LTD","latestPrice":0.034,"timestamp":1791436320000,"preClose":0.035,"halted":0,"volume":320326,"delay":0,"changeRate":-0.028571428571428595,"nameEN":"BLACKSTONE MINERALS LTD","floatShares":1378369438,"shares":1719359861,"eps":-0.008563,"marketStatus":"Closed","change":-0.001,"latestTime":"10-08 16:12:00 AEDT","open":0.034,"high":0.035,"low":0.034,"amount":10899,"amplitude":0.028571,"askPrice":0.035,"askSize":625347,"bidPrice":0.034,"bidSize":507102,"shortable":3,"etf":0,"ttmEps":-0.008563,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791500400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.035,"openAndCloseTimeList":[[1791414000000,1791435600000]],"volumeRatio":0.50361,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"BSX.AU","preClose":0.038,"auctionPrice":0.036,"auctionVolume":16046,"auction":3,"marketStatus":"盘后竞价","timestamp":1791176881523}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BSX.AU\",,,,,undefined,":{"symbol":"BSX.AU","floatShares":1378369438,"roa":"-5.95%","roe":"-11.34%","lyrEps":-0.008563,"volumeRatio":0.50361,"shares":1719359861,"dividePrice":0,"high":0.035,"amplitude":0.028571,"preClose":0.035,"low":0.034,"week52Low":0.028,"pbRate":"0.67","psRate":"143.95","week52High":0.085,"institutionHeld":0,"latestPrice":0.034,"committee":-0.104415,"eps":-0.008563,"divideRate":0,"volume":320326,"delay":0,"ttmEps":-0.008563,"open":0.034,"prevYearClose":0.055,"prevWeekClose":0.038,"prevMonthClose":0.037,"prevQuarterClose":0.037,"fiveDayClose":0.038,"twentyDayClose":0.047,"sixtyDayClose":0.041},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BSX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BSX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BSX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673196990","title":"Evercore ISI Adjusts Price Target on Boston Scientific to $52 From $65","url":"https://stock-news.laohu8.com/highlight/detail?id=2673196990","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673196990?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:11","pubTimestamp":1791385869,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) has an average rating of overweight and mean price target of $58.79, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0138981039.USD","IE0002141913.USD","LU0345769128.USD","LU1804176565.USD","LU0823417737.USD","LU0077335932.USD","LU0238689110.USD","LU0823416689.USD","LU1983299246.USD","LU1989764664.SGD","LU2506952097.USD","LU2362541513.USD","BSX.AU","LU0251132253.USD","BSX","IE0009355771.USD","LU1718418525.SGD","LU0187121727.USD","LU2506952170.USD","LU2357305700.SGD","LU0048584097.USD","BK4588","LU0432979614.USD","LU1366192091.USD","LU2491049909.HKD","IE00BJT1NW94.SGD","LU1153585028.USD","LU2362540622.SGD","LU1057294990.SGD","LU2491050154.USD","LU2244417387.USD","LU1989764748.USD","IE00BJJMRZ35.SGD","LU0225283273.USD","LU0114720955.EUR","BK4504","BK4585","BK4082","LU0882574055.USD","LU1791710400.SGD","LU0011850046.USD","SG9999013999.USD","LU1720051017.SGD","LU2112291526.USD","SG9999001176.SGD","LU2506951958.HKD","IE00B2B36J28.USD","LU1023059063.AUD","LU0345769631.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673044217","title":"Citigroup Adjusts Price Target on Boston Scientific to $48 From $50, Keeps Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2673044217","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673044217?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:22","pubTimestamp":1791199367,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) has an average rating of overweight and mean price target of $59.37, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0238689110.USD","LU0266013472.USD","LU0528227936.USD","BSX.AU","BSX","LU0432979614.USD","LU0950375773.USD","LU0251132253.USD","LU0114720955.EUR","LU0353189680.USD","BK7095","LU0048584097.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0225283273.USD","LU0353189763.USD","LU2362540622.SGD","LU2244417387.USD","LU0267386448.USD","LU1791710582.SGD","LU2357305700.SGD","LU2112291526.USD","BK4581","LU2506952170.USD","LU0345769631.USD","LU0823417653.USD","LU2087625088.SGD","LU2491049909.HKD","IE0009355771.USD","LU2506951875.HKD","LU1720051017.SGD","BK4585","LU0345769128.USD","IE00BJT1NW94.SGD","BK4588","LU1983299246.USD","LU2362541513.USD","LU2491050154.USD","LU1548497426.USD","BK4082","LU2265009873.SGD","LU1989764664.SGD","LU1989772840.SGD","LU2506951958.HKD","SG9999001176.USD","LU1153585028.USD","LU1061106388.HKD","LU0122379950.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669616688","title":"Oppenheimer Adjusts Price Target on Boston Scientific to $65 From $85, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2669616688","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669616688?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:00","pubTimestamp":1789995653,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) has an average rating of overweight and mean price target of $59.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2362541513.USD","IE00BJT1NW94.SGD","BK4581","LU0114720955.EUR","IE0002141913.USD","LU1548497426.USD","LU2491050071.SGD","LU0353189680.USD","LU1718418525.SGD","LU0138981039.USD","LU2491049909.HKD","LU0823417737.USD","LU1791710582.SGD","LU0882574055.USD","LU1366192091.USD","LU0267386448.USD","LU2362541273.HKD","LU2242649171.HKD","LU0353189763.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU1153585028.USD","LU0345769128.USD","LU1720051017.SGD","LU1989772840.SGD","IE00B2B36J28.USD","LU2491050154.USD","LU1989764664.SGD","BK4588","BSX.AU","IE0009355771.USD","BSX","LU2087625088.SGD","LU0122379950.USD","LU2324357040.USD","LU1057294990.SGD","LU0048584097.USD","IE00B4R5TH58.HKD","BK7095","LU0225283273.USD","LU1804176565.USD","SG9999001176.SGD","SGXZ57979304.SGD","LU0077335932.USD","LU1023059063.AUD","LU0823416689.USD","LU2265009873.SGD","BK4082","LU1720051108.HKD","LU2357305700.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668762991","title":"Boston Scientific Shares Fall After Citigroup Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2668762991","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668762991?lang=en_us&edition=fundamental","pubTime":"2026-09-18 02:32","pubTimestamp":1789669958,"startTime":"0","endTime":"0","summary":"Boston Scientific  shares were down over 1% in Thursday trading after Citigroup downgraded the stock to neutral from buy, and cut its price target to $50 from $57.Trading volume stood at more than 16.1 million shares, compared with a daily average of about 20.4 million.Price: 43.35, Change: -0.56, Percent Change: -1.29","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BSX.AU","BK7095","LU2265009873.SGD","LU1989772840.SGD","LU0187121727.USD","LU0823416689.USD","LU2362541273.HKD","LU1366192091.USD","LU0950375773.USD","BK4504","LU2491050071.SGD","LU2506951958.HKD","LU2506952170.USD","LU2244417387.USD","LU1720051017.SGD","LU1989764664.SGD","IE00BFTCPJ56.SGD","SGXZ57979304.SGD","LU0345769631.USD","LU0138981039.USD","LU1291159041.SGD","LU0251132253.USD","LU2242649171.HKD","LU0353189680.USD","LU1548497426.USD","LU1718418525.SGD","IE00B4R5TH58.HKD","LU2324357040.USD","LU2362540622.SGD","BSX","IE00BJT1NW94.SGD","LU0225283273.USD","SG9999001176.USD","LU2357305700.SGD","LU2491050154.USD","LU0077335932.USD","LU1720051108.HKD","IE00BJJMRZ35.SGD","LU1804176565.USD","IE00B2B36J28.USD","IE0002141913.USD","LU0011850046.USD","LU0528227936.USD","LU1989764748.USD","LU0048584097.USD","LU1023059063.AUD","LU1989771016.USD","IE0009355771.USD","LU2362541513.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668296800","title":"Citigroup Downgrades Boston Scientific to Neutral From Buy, Adjusts Price Target to $50 From $57","url":"https://stock-news.laohu8.com/highlight/detail?id=2668296800","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668296800?lang=en_us&edition=fundamental","pubTime":"2026-09-17 17:29","pubTimestamp":1789637349,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) has an average rating of buy and mean price target of $60.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1548497426.USD","LU1153585028.USD","LU1718418525.SGD","LU1720051108.HKD","LU2357305700.SGD","LU0011850046.USD","SG9999001176.USD","LU0251132253.USD","LU0187121727.USD","LU0048584097.USD","LU0882574055.USD","LU1291159041.SGD","LU1989764664.SGD","LU1057294990.SGD","LU2506951958.HKD","LU2506952097.USD","BSX.AU","LU1983299246.USD","LU0353189680.USD","LU1791710582.SGD","LU0823417737.USD","LU2265009873.SGD","LU0266013472.USD","BK4581","LU0345769631.USD","BSX","LU0823416689.USD","LU2112291526.USD","LU2506951875.HKD","BK7095","LU0432979614.USD","LU2324357040.USD","LU2362540622.SGD","BK4504","LU1023059063.AUD","LU1989771016.USD","LU1720051017.SGD","SG9999001176.SGD","LU0238689110.USD","LU0138981039.USD","LU0225283273.USD","LU0267386448.USD","LU1061106388.HKD","BK4588","LU2242649171.HKD","LU2087625088.SGD","LU1989772840.SGD","LU2506952170.USD","LU0077335932.USD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372816","title":"Boston Scientific Cyberattack Could Extend Rebound Timeline, Truist Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372816","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372816?lang=en_us&edition=fundamental","pubTime":"2026-09-09 02:53","pubTimestamp":1788893621,"startTime":"0","endTime":"0","summary":"Boston Scientific's  cyberattack could extend the timeframe for a sustainable stock rebound, but the company still offers relative risk/reward skewed to the upside over the next six to 12 months, Truist Securities said in a note Tuesday.The company earlier said it is unlikely to meet its Q3 and full-year 2026 net sales growth and adjusted earnings per share guidance ranges.Truist said the cyberattack's impact on revenue and EPS remains unframed, while recent company updates indicate that the distribution network has been substantially restored and manufacturing has resumed across most facilities globally.Truist said 2026 and likely 2027 estimates will need to come down, with the Q3 earnings call in October the next likely official guidance update.The brokerage expects upcoming investor presentations to provide additional information on the cyberattack recovery pathway, affected business segments and potential share loss or recapture.Truist maintained a buy rating and a $57 price target","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0823416689.USD","LU2506952170.USD","LU0225283273.USD","LU0238689110.USD","BSX.AU","LU1720051017.SGD","IE0009355771.USD","LU1989772923.USD","LU2506951958.HKD","LU2244417387.USD","LU0353189763.USD","BK7095","LU1718418525.SGD","LU1791710582.SGD","IE00B4R5TH58.HKD","BK4588","BK4504","IE00BJJMRZ35.SGD","LU0251132253.USD","LU2112291526.USD","LU0528227936.USD","LU2362541273.HKD","IE00B2B36J28.USD","LU1791710400.SGD","SG9999001176.USD","LU1720051108.HKD","LU0823417737.USD","LU1061106388.HKD","LU0882574055.USD","BSX","LU2265009873.SGD","LU2491049909.HKD","SGXZ57979304.SGD","LU0345769631.USD","IE00BFTCPJ56.SGD","LU1291159041.SGD","LU0187121727.USD","LU0950375773.USD","LU1989764664.SGD","LU0048584097.USD","LU0345769128.USD","LU1804176565.USD","LU2324357040.USD","LU2506951875.HKD","LU1983299246.USD","LU1989772840.SGD","LU2362540622.SGD","BK4082","LU0267386448.USD","SG9999001176.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666712993","title":"Resmed Inc Stock (RMD) Moved Down by 3.15% on Sep 8: What Investors Need To Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2666712993","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666712993?lang=en_us&edition=fundamental","pubTime":"2026-09-09 00:15","pubTimestamp":1788884129,"startTime":"0","endTime":"0","summary":"• ResMed faced selling pressure due to Astral ventilator suspension expenses and margin pressures.\n• Sector sentiment remains constrained by GLP-1 concerns and potential Philips market re-entry.\n• ResMed completed the MatrixCare divestiture, funding accelerated share repurchases and increased dividends.","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262156444-market-movers-rmd-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051017.SGD","BK4581","LU2112291526.USD","IHI","LU2506952170.USD","TMO","LGHT","LU0170899867.USD","RMD","LU2506951875.HKD","LU0128525929.USD","LU0823416689.USD","BSX.AU","LU1061106388.HKD","GNMX","LU0345769128.USD","BK4585","LU0187121727.USD","LU1291159041.SGD","LU1720051108.HKD","BSX","LU0096362180.USD","BK4211","BK4533","IE0009355771.USD","BK7007","TMED","IE0002141913.USD","LU1983299246.USD","LU2720916845.USD","LU2125910336.SGD","HRTS","LU0289739699.SGD","LU2362540622.SGD","FMED","SYK","BK4082","LU0048573561.USD","IE00BQXX3F31.USD","LU2357305700.SGD","LU0251131958.USD","LU1923621640.USD","LU0353189763.USD","LU2041044095.USD","LU2265009873.SGD","LU2125910179.SGD","LU1989764748.USD","RMD.AU","ISBC","LU1791710400.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662741525","title":"Update: Boston Scientific Shares Fall After Catheter Recall","url":"https://stock-news.laohu8.com/highlight/detail?id=2662741525","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662741525?lang=en_us&edition=fundamental","pubTime":"2026-08-27 03:40","pubTimestamp":1787773225,"startTime":"0","endTime":"0","summary":"Boston Scientific  shares fell 2.7% in Wednesday trading after the company recalled certain percutaneous catheters due to the risk of arterial sheath tip separation, which could lead to complications from a retained tip, according to the US Food and Drug Administration.The affected products are certain lots of the company's ENROUTE Transcarotid Neuroprotection System and ENROUTE Transcarotid Neuroprotection System Plus devices, according to the statement. The FDA warned that potential complications include embolism and stroke, among others.Boston Scientific has reported one serious injury related to the issue, the FDA said.Price: 48.52, Change: -1.35, Percent Change: -2.70","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0882574055.USD","LU0251132253.USD","LU1291159041.SGD","LU2087625088.SGD","SG9999001176.SGD","LU1366192091.USD","LU0077335932.USD","LU2357305700.SGD","LU0950375773.USD","LU1720051108.HKD","LU1989772923.USD","LU0122379950.USD","LU1989772840.SGD","IE00BJT1NW94.SGD","LU2362541513.USD","LU0432979614.USD","LU2506952097.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0238689110.USD","LU0353189680.USD","LU0114720955.EUR","LU0267386448.USD","BK4082","LU0266013472.USD","LU0345769631.USD","LU2242649171.HKD","LU2265009873.SGD","LU2506951875.HKD","LU1061106388.HKD","SGXZ57979304.SGD","BK7095","IE0009355771.USD","LU2362541273.HKD","LU1791710582.SGD","BK4504","LU0528227936.USD","BSX","LU2324357040.USD","LU0011850046.USD","LU0138981039.USD","LU0048584097.USD","SG9999001176.USD","BK4581","LU1804176565.USD","BSX.AU","LU2506951958.HKD","LU1720051017.SGD","LU1548497426.USD","LU0345769128.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662433427","title":"Boston Scientific Recalling Thousands of Percutaneous Catheters","url":"https://stock-news.laohu8.com/highlight/detail?id=2662433427","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662433427?lang=en_us&edition=fundamental","pubTime":"2026-08-26 23:36","pubTimestamp":1787758612,"startTime":"0","endTime":"0","summary":"Boston Scientific  is recalling thousands of its percutaneous catheters due to possible arterial sheath tip separation that could lead to complications with a retained tip, the US Food and Drug Administration confirmed in a Wednesday statement.The affected products are certain lots of the company's ENROUTE Transcarotid Neuroprotection System and ENROUTE Transcarotid Neuroprotection System Plus devices, according to the statement. The FDA warned that potential complications include embolism and stroke, among others.Boston Scientific has reported one serious injury related to the issue, the FDA said.Price: 47.67, Change: -2.20, Percent Change: -4.40","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1023059063.AUD","LU2242649171.HKD","LU1791710582.SGD","LU2506952170.USD","LU1989772923.USD","LU2491050154.USD","LU0345769631.USD","LU1548497426.USD","LU2265009873.SGD","BK4504","IE00BJT1NW94.SGD","LU0432979614.USD","LU0267386448.USD","LU1057294990.SGD","LU0048584097.USD","LU0823417737.USD","LU0950375773.USD","LU1983299246.USD","LU1791710400.SGD","BK4585","LU0077335932.USD","LU0528227936.USD","LU0251132253.USD","LU2087625088.SGD","LU0187121727.USD","IE00B4R5TH58.HKD","LU1061106388.HKD","LU1720051017.SGD","BSX.AU","IE00B2B36J28.USD","BSX","LU0114720955.EUR","LU0122379950.USD","LU2244417387.USD","LU2112291526.USD","SG9999001176.SGD","SGXZ57979304.SGD","BK4082","LU0823416689.USD","LU0011850046.USD","LU2506951875.HKD","LU0882574055.USD","LU2362541513.USD","LU1720051108.HKD","LU2362540622.SGD","LU1153585028.USD","IE00BJJMRZ35.SGD","LU1989772840.SGD","LU2362541273.HKD","LU1989764748.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662712851","title":"Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2662712851","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662712851?lang=en_us&edition=fundamental","pubTime":"2026-08-26 21:18","pubTimestamp":1787750291,"startTime":"0","endTime":"0","summary":"Healthcare stocks were leaning lower pre-bell Wednesday, with the State Street Health Care Select Sector SPDR ETF  down 0.1% and the iShares Biotechnology ETF  declining by 0.5%.Boston Scientific  has identified a cybersecurity incident that affected its certain IT systems and led to global disruption in operations, the company said in a filing. Boston Scientific shares were down more than 5% premarket.Jazz Pharmaceuticals'  wholly owned subsidiary plans to offer $1 billion of exchangeable senior notes due 2032, the company said. Jazz Pharmaceuticals stock was down more than 2% pre-bell.Summit Therapeutics  partner Akeso reported \"positive\" results from a phase 3 trial of ivonescimab plus chemotherapy, compared with durvalumab plus chemotherapy as a first-line treatment of advanced biliary tract cancer. Shares of Summit Therapeutics were up more than 12% premarket.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2488822045.USD","LU2357305700.SGD","HCSG","BSX.AU","IE0002141913.USD","LU2506951875.HKD","LU2491050154.USD","BK7095","BK4082","LU0950375773.USD","XLV","LU0345769631.USD","SMMT","LU1989772923.USD","BK4504","BK4581","LU0029874061.USD","XBI","LU0528227936.USD","IE0009355771.USD","JAZZ","LU0823417653.USD","LU0238689110.USD","SGXZ57979304.SGD","LU0187121727.USD","LU2362541273.HKD","LU0823416689.USD","LU0225283273.USD","LU0109394709.USD","LU0114720955.EUR","LABU","LU0128526141.USD","LU1291159041.SGD","LU1791710400.SGD","LU1023059063.AUD","LU1989771016.USD","BSX","LU2362541513.USD","IE00B4R5TH58.HKD","LU0266013472.USD","LU1153585028.USD","LU1061106388.HKD","LU2491049909.HKD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LU0077335932.USD","IBB","LU1989764664.SGD","LU0011850046.USD","LU2244417387.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661721736","title":"Should Boston Scientific’s Shift Toward Capital Spending and External Innovation Require Action From (BSX) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2661721736","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661721736?lang=en_us&edition=fundamental","pubTime":"2026-08-23 08:32","pubTimestamp":1787445157,"startTime":"0","endTime":"0","summary":"Boston Scientific recently shifted its capital budget above its research budget for the first time in fifteen years, while planning seven new product launches and pursuing run-rate savings from cost programs to restore growth amid competitive pressure in Electrophysiology and softer WATCHMAN revenues.\nAn interesting twist is that two of the seven growth-driving launches are coming from outside Boston Scientific’s own labs, underscoring a greater reliance on external innovation alongside...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/should-boston-scientifics-shift-toward-capital-spending-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/should-boston-scientifics-shift-toward-capital-spending-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0077335932.USD","LU0138981039.USD","IE00B4R5TH58.HKD","LU0114720955.EUR","BSX.AU","LU0353189680.USD","LU2112291526.USD","LU0432979614.USD","BK4504","ISBC","LU2362541273.HKD","LU1989764748.USD","LU2244417387.USD","BK7095","IE00BJJMRZ35.SGD","LU0882574055.USD","BK4581","BK4211","LU0266013472.USD","LU1291159041.SGD","SG9999013999.USD","LU1989764664.SGD","LU0267386448.USD","LU2506952170.USD","LU1720051108.HKD","LU1791710400.SGD","LU2265009873.SGD","LU2491050154.USD","IE00BJT1NW94.SGD","SGXZ57979304.SGD","BK4082","LU0823417737.USD","LU0345769128.USD","IE0002141913.USD","LU0122379950.USD","LU2362541513.USD","BSX","LU0823416689.USD","LU0823417653.USD","LU0528227936.USD","LU2506951958.HKD","LU1989771016.USD","LU1153585028.USD","IE00BFTCPJ56.SGD","SG9999001176.USD","LU0950375773.USD","LU1366192091.USD","LU0353189763.USD","LU1023059063.AUD","LU2506952097.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661230609","title":"Boston Scientific (BSX) Rebounds Sharply, Is The Stock Still A Bargain?","url":"https://stock-news.laohu8.com/highlight/detail?id=2661230609","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661230609?lang=en_us&edition=fundamental","pubTime":"2026-08-21 05:21","pubTimestamp":1787260916,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) is drawing investor attention after its recent share move, with the stock closing at $52.01 on 18 August 2026. That price shift puts fresh focus on how its medical device business supports current valuation.\nSee our latest analysis for Boston Scientific.\nOver the past month Boston Scientific has seen a strong 30 day share price return of 18.83%, although the share price is still down 45.08% year to date and the 1 year total shareholder return is down 50.96%. This...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-rebounds-sharply-is-the-stock-still-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-rebounds-sharply-is-the-stock-still-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2491050071.SGD","LU2506951958.HKD","LU0432979614.USD","SG9999013999.USD","LU2244417387.USD","LU1153585028.USD","LU0823417653.USD","LU0267386448.USD","BSX","BK4082","LU0823417737.USD","LU1548497426.USD","LU2265009873.SGD","LU2357305700.SGD","LU2491049909.HKD","IE00BJT1NW94.SGD","LU0345769128.USD","LU1366192091.USD","LU2242649171.HKD","LU0266013472.USD","LU0048584097.USD","IE00BJJMRZ35.SGD","LU0353189763.USD","LU1989764748.USD","SG9999001176.SGD","LU1804176565.USD","LU1291159041.SGD","LU1989771016.USD","LU2506952170.USD","SG9999001176.USD","LU1989772840.SGD","LU0225283273.USD","LU1791710582.SGD","BK4581","LU0114720955.EUR","LU2506951875.HKD","LU0187121727.USD","IE00B2B36J28.USD","LU2087625088.SGD","LU2324357040.USD","LU2362541273.HKD","LU0122379950.USD","BSX.AU","IE00BFTCPJ56.SGD","LU0353189680.USD","IE00B4R5TH58.HKD","BK7095","LU0882574055.USD","LU0238689110.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658930168","title":"Resmed Inc Stock (RMD) Moved Up by 3.01% on Aug 10: Key Drivers Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=2658930168","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658930168?lang=en_us&edition=fundamental","pubTime":"2026-08-10 23:15","pubTimestamp":1786374931,"startTime":"0","endTime":"0","summary":"• ResMed reported strong recurring revenue from its AirSense platform and software ecosystem.\n• Clinical insights suggest GLP-1 drugs increase sleep apnea diagnosis rates and patient engagement.\n• ResMed solidified market share as its primary competitor faces ongoing regulatory constraints.","market":"hk","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262093058-market-movers-rmd-20260810","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2265009873.SGD","BSX.AU","LU0238689110.USD","LU1093756325.SGD","IHI","LU0114720955.EUR","LU1093756168.USD","LU2008162690.USD","LU0353189763.USD","LU0432979614.USD","ISUL","LU2491049909.HKD","BSX","BK7007","IHF","LU1974910355.USD","LU0048584097.USD","LU0225283273.USD","IE0002141913.USD","LGHT","RMD.AU","SG9999001176.SGD","LU2362540622.SGD","BK4567","LU0011850046.USD","HUM","LU0528227936.USD","SG9999001176.USD","LU0122379950.USD","BK4533","LU0267386448.USD","LU2491050071.SGD","LU2063271972.USD","RMD","HUM.AU","LU0070302665.USD","LU0823417653.USD","LU2087625088.SGD","LU1951198990.SGD","FXH","LU2362541513.USD","IE00BFXG0V08.USD","LU2177674079.SGD","LU2106854487.HKD","LU1791710400.SGD","EKG","LU1989771016.USD","LU1868836757.USD","ISRG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656485333","title":"Why Boston Scientific (BSX) Is Up 5.6% After Mixed Q2, Recall News And Guidance Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2656485333","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656485333?lang=en_us&edition=fundamental","pubTime":"2026-08-02 23:17","pubTimestamp":1785683857,"startTime":"0","endTime":"0","summary":"In late July 2026, Boston Scientific reported second-quarter results showing sales rising to US$5,442 million and net income reaching US$907 million, alongside updated guidance calling for 2026 reported net sales growth of about 5.5% to 6.5% and third-quarter growth of about 3% to 5% versus the prior year.\nAt the same time, the company issued a voluntary Class II recall of its Rapid Refill Continuous Injection System due to syringe connection risks, highlighting ongoing product quality and...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/why-boston-scientific-bsx-is-up-56-after-mixed-q2-recall-new","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/why-boston-scientific-bsx-is-up-56-after-mixed-q2-recall-new","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2324357040.USD","LU2506951875.HKD","LU0266013472.USD","SG9999013999.USD","BSX.AU","IE0002141913.USD","LU0238689110.USD","LU1791710400.SGD","LU2244417387.USD","IE00B2B36J28.USD","LU0122379950.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU1023059063.AUD","LU1720051017.SGD","LU0823416689.USD","IE00BJT1NW94.SGD","LU2506951958.HKD","LU0950375773.USD","SG9999001176.SGD","BK4588","LU1989771016.USD","LU2362541273.HKD","LU1061106388.HKD","LU0353189680.USD","SGXZ57979304.SGD","LU1989764748.USD","BK4581","LU0353189763.USD","LU1989772923.USD","LU0823417653.USD","LU0187121727.USD","LU2357305700.SGD","IE0009355771.USD","LU1057294990.SGD","LU0138981039.USD","LU0048584097.USD","LU1718418525.SGD","LU2242649171.HKD","BK7095","LU1989764664.SGD","IE00BFTCPJ56.SGD","LU0267386448.USD","LU1366192091.USD","LU1989772840.SGD","LU0077335932.USD","LU0251132253.USD","BSX","BK4504","LU0345769631.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655835586","title":"Boston Scientific (BSX) Stock Ignores Margin Strength As Growth Outlook Softens","url":"https://stock-news.laohu8.com/highlight/detail?id=2655835586","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655835586?lang=en_us&edition=fundamental","pubTime":"2026-07-31 15:21","pubTimestamp":1785482500,"startTime":"0","endTime":"0","summary":"Boston Scientific stock barely flinched after earnings, slipping only 0.1% and leaving shares roughly flat over the past week and month despite a sharp 18.6% decline over the last 90 days. The market is treating this quarter as business as usual. The numbers suggest something more important is happening inside the income statement.\nThe core story this quarter is margins. Adjusted gross margin reached 70.3% and adjusted operating margin hit 28.4%, both higher than a year ago, while trailing...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-stock-ignores-margin-strength-as-growt","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-stock-ignores-margin-strength-as-growt","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1548497426.USD","BK4585","LU2506951875.HKD","LU2362540622.SGD","SG9999013999.USD","BSX.AU","LU0823417737.USD","IE0002141913.USD","LU0238689110.USD","LU1791710400.SGD","LU0122379950.USD","IE00B4R5TH58.HKD","LU1720051017.SGD","LU0432979614.USD","LU1153585028.USD","LU1983299246.USD","LU0011850046.USD","LU2506951958.HKD","LU0950375773.USD","BK4588","LU1989771016.USD","LU2112291526.USD","LU2362541273.HKD","LU1061106388.HKD","SGXZ57979304.SGD","LU1989764748.USD","BK4581","LU0353189763.USD","LU0187121727.USD","LU2357305700.SGD","LU1291159041.SGD","LU2491050071.SGD","LU0138981039.USD","LU1804176565.USD","LU2491049909.HKD","LU1718418525.SGD","LU2242649171.HKD","BK7095","BK4082","LU0528227936.USD","LU1989764664.SGD","LU2506952097.USD","LU0267386448.USD","LU1989772840.SGD","LU0077335932.USD","LU2087625088.SGD","LU0345769128.USD","LU0251132253.USD","BSX","LU0345769631.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655021328","title":"Boston Scientific's Watchman Slowdown Raises Utilization Questions, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2655021328","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655021328?lang=en_us&edition=fundamental","pubTime":"2026-07-31 00:55","pubTimestamp":1785430539,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) guidance cut was driven by weakness in its Watchman and electrophysiology or EP businesses, with the gap versus initial long-range targets widening into 2027, Oppenheimer said ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1548497426.USD","LU0345769631.USD","IE00B2B36J28.USD","LU0077335932.USD","LU1791710582.SGD","IE00BJJMRZ35.SGD","LU2506952170.USD","LU2112291526.USD","BK4504","LU0187121727.USD","BK4588","LU0266013472.USD","LU1061106388.HKD","OPY","LU2491049909.HKD","BK4585","LU1989772840.SGD","LU0114720955.EUR","LU0528227936.USD","LU0823417653.USD","LU0225283273.USD","SGXZ57979304.SGD","LU1153585028.USD","LU2362541273.HKD","LU0882574055.USD","IE0009355771.USD","LU1983299246.USD","LU2506952097.USD","LU2265009873.SGD","LU0823416689.USD","LU1023059063.AUD","LU1989771016.USD","LU0238689110.USD","BK4082","LU0138981039.USD","LU1791710400.SGD","LU2362540622.SGD","LU1057294990.SGD","LU2491050154.USD","SG9999013999.USD","LU0267386448.USD","LU1804176565.USD","IE00BFTCPJ56.SGD","LU1989764748.USD","BSX","LU0011850046.USD","LU2324357040.USD","BSX.AU","LU1989764664.SGD","LU2506951875.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655804502","title":"Boston Scientific Lowered Full-Year Guidance on Headwinds in Electrophysiology, Watchman Portfolios, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2655804502","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655804502?lang=en_us&edition=fundamental","pubTime":"2026-07-30 23:57","pubTimestamp":1785427033,"startTime":"0","endTime":"0","summary":"Boston Scientific (BSX) reported Q2 revenue and EPS that beat expectations but lowered its full-year guidance, which was largely expected given known headwinds in its Electrophysiology and Watchman po","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0238689110.USD","LU1023059063.AUD","LU1791710400.SGD","LU0823416689.USD","LU2324357040.USD","LU2362540622.SGD","LU0077335932.USD","LU0048584097.USD","LU1548497426.USD","SGXZ57979304.SGD","IE00BFTCPJ56.SGD","LU0011850046.USD","LU2242649171.HKD","LU1720051017.SGD","BSX","LU2506951875.HKD","LU1791710582.SGD","LU0882574055.USD","SG9999001176.SGD","LU1804176565.USD","LU2244417387.USD","LU2506952097.USD","LU1291159041.SGD","LU1061106388.HKD","IE00B2B36J28.USD","LU2357305700.SGD","LU0353189763.USD","LU1057294990.SGD","LU1720051108.HKD","LU0823417653.USD","LU2491050071.SGD","BK4082","BK4588","IE0009355771.USD","LU1153585028.USD","LU2506952170.USD","LU0187121727.USD","LU1983299246.USD","LU0138981039.USD","LU2506951958.HKD","BK4504","BSX.AU","LU0345769631.USD","LU2491049909.HKD","LU0345769128.USD","LU0353189680.USD","BK4581","LU0823417737.USD","SG9999001176.USD","LU1989764664.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655869445","title":"GUIDANCE: (BSX) Boston Scientific Expects 2026 Adjusted EPS Range $3.28 to $3.32, vs. FactSet Est of $3.36","url":"https://stock-news.laohu8.com/highlight/detail?id=2655869445","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655869445?lang=en_us&edition=fundamental","pubTime":"2026-07-29 18:32","pubTimestamp":1785321171,"startTime":"0","endTime":"0","summary":"GUIDANCE: (BSX) Boston Scientific Expects 2026 Adjusted EPS Range $3.28 to $3.32, vs. FactSet Est of $3.36","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BSX","BSX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655783839","title":"Boston Scientific (BSX) Recalls Rapid Refill Injection System Over Syringe Detachment Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2655783839","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655783839?lang=en_us&edition=fundamental","pubTime":"2026-07-29 02:14","pubTimestamp":1785262497,"startTime":"0","endTime":"0","summary":"Boston Scientific has issued a voluntary Class II recall of its Rapid Refill Continuous Injection System.\nThe recall is linked to a risk that syringes may loosen or detach, which could affect device performance and procedural outcomes.\nThe action covers a large number of units distributed in the US and international markets.\n\nFor investors watching Boston Scientific, ticker NYSE:BSX, this recall comes amid a mixed share performance backdrop. The stock closed at $45.51, with returns up 4.0%...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-recalls-rapid-refill-injection-system","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-recalls-rapid-refill-injection-system","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1291159041.SGD","SG9999001176.SGD","BK4585","LU0077335932.USD","LU2357305700.SGD","LU0950375773.USD","LU1989772923.USD","LU1023059063.AUD","LU0823417653.USD","LU0122379950.USD","LU0225283273.USD","LU1989772840.SGD","LU0432979614.USD","LU2506952097.USD","IE00B4R5TH58.HKD","LU2244417387.USD","LU0353189680.USD","LU0345769631.USD","LU2242649171.HKD","LU2506951875.HKD","LU1983299246.USD","LU1061106388.HKD","LU0353189763.USD","IE00BFTCPJ56.SGD","LU0187121727.USD","SGXZ57979304.SGD","IE0009355771.USD","LU0823416689.USD","LU2362541273.HKD","LU1791710582.SGD","LU2491050071.SGD","BK4504","LU2112291526.USD","LU0528227936.USD","BSX","LU1989771016.USD","LU0138981039.USD","LU0048584097.USD","LU1791710400.SGD","SG9999001176.USD","BK4581","LU1804176565.USD","LU1718418525.SGD","LU0823417737.USD","BSX.AU","LU2506951958.HKD","IE00BJJMRZ35.SGD","LU1989764748.USD","LU1548497426.USD","LU0345769128.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655884305","title":"Boston Scientific Has Underappreciated Growth Drivers, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2655884305","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655884305?lang=en_us&edition=fundamental","pubTime":"2026-07-29 02:10","pubTimestamp":1785262202,"startTime":"0","endTime":"0","summary":"Boston Scientific  has underappreciated growth drivers beyond its electrophysiology and Watchman franchises that should support continued high-single-digit organic growth, UBS said in a note Tuesday.The firm pointed to coronary intravascular lithotripsy and renal denervation products expected in 2027 and 2028, representing a combined $2.5 billion served market, along with Empower leadless pacemaker launch in 2027 that could help the company gain share in a structurally higher-growth cardiac rhythm management market.UBS said management's lowered growth outlook for electrophysiology and Watchman is already reflected in Street models, giving the company room to shift focus toward other high-growth areas.The firm added that current share pricing implies sales declines through 2029, versus its own and consensus estimates for high-single-digit growth, suggesting the recent pullback is overdone.UBS assumed coverage of Boston Scientific with a buy rating and $74 price target.Price: 46.48, Chan","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1989764748.USD","BSX.AU","LU1791710400.SGD","IE00BJT1NW94.SGD","LU0823417737.USD","SG9999001176.SGD","LU0345769128.USD","LU0138981039.USD","LU0823417653.USD","LU2242649171.HKD","LU1720051108.HKD","LU1366192091.USD","LU1291159041.SGD","LU2506952097.USD","LU0345769631.USD","LU0528227936.USD","LU0353189680.USD","IE00BJJMRZ35.SGD","LU0048584097.USD","LU2087625088.SGD","SG9999013999.USD","LU0950375773.USD","LU0251132253.USD","LU1023059063.AUD","LU2244417387.USD","LU2265009873.SGD","BK4585","LU2324357040.USD","LU0122379950.USD","LU0432979614.USD","SGXZ57979304.SGD","LU1989772923.USD","LU0114720955.EUR","LU2362541513.USD","BK4082","BSX","IE0002141913.USD","LU1804176565.USD","LU0187121727.USD","LU2491050071.SGD","LU0238689110.USD","IE0009355771.USD","LU0225283273.USD","BK7095","LU0882574055.USD","LU0823416689.USD","LU1057294990.SGD","IE00B4R5TH58.HKD","LU2506951958.HKD","LU1989771016.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":46,"code":"91000000","status":"200"}]}}